VivoSeq
Other

Post Operative Cognitive Dysfunction

0

Pipeline Programs

4

Active Trials

0

Companies Involved

Post Operative Cognitive Dysfunction is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

85/100

Attrition Rate

8/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

26

clinical trials

Completed11 · 42%
Unknown status9 · 35%
Not yet recruiting2 · 8%
Recruiting1 · 4%
Withdrawn1 · 4%
Terminated1 · 4%
Other1 · 4%

Trial Activity

26 trials

The Effect of Ketamine on Postoperative Cognitive Dysfunction.
Completed··Phase 4·NCT04321746·45 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)